C12N 2710/24133
Use of viral protein as therapeutic agent other than vaccine
Official title: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
C12N2710/24133 (Use of viral protein as therapeutic agent other than vaccine) appears on 14 US grants and 26 published applications in this corpus.
Search patents in C12N- Granted patents
- 14
- Published applications
- 26
- Assignees
- 23
- Inventors
- 76
- Latest grant
- 30 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 2 |
| 2013 | 0 | 1 |
| 2014 | 0 | 1 |
| 2015 | 1 | 0 |
| 2016 | 0 | 2 |
| 2017 | 0 | 1 |
| 2018 | 1 | 0 |
| 2019 | 2 | 2 |
| 2020 | 2 | 4 |
| 2021 | 0 | 3 |
| 2022 | 1 | 3 |
| 2023 | 2 | 3 |
| 2024 | 3 | 2 |
| 2025 | 1 | 1 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Recombinant viral vector, immunogenic composition comprising same, and uses30 Dec 2025US 12,508,309 B2Vacdiagn Biotechnology Co., Ltd
- Engineered immunostimulatory bacterial strains and uses thereof18 Jun 2024US 12,012,600 B2Actym Therapeutics, Inc.
- Compositions and methods for modulating inflammatory responses28 May 2024US 11,993,632 B2Duke University
- Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy21 May 2024US 11,986,503 B2Memorial Sloan Kettering Cancer Center
- Enhanced systems for cell-mediated oncolytic viral therapy23 May 2023US 11,655,455 B2Calidi Biotherapeutics, Inc.
- Oncolytic virus simultaneously expressing cd55 and cd591 Jan 2026US 2026/0000722 A1Sillajen, Inc.
- Methods for production of therapeutic immune cells having enhanced metabolic fitness and compositions thereof6 Mar 2025US 2025/0074950 A1Board of Regents, The University of Texas System
- Self-amplifying messenger rna12 Sep 2024US 2024/0301006 A1Glaxosmithkline Biologicals SA
- Chimeric antigen receptor targeting oncolytic virus-derived protein, immunocyte expressing same, and uses of both6 Jun 2024US 2024/0181058 A1Bionoxx Inc.
- Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human flt3l or gm-csf for cancer immunotherapy5 Oct 2023US 2023/0310526 A1Memorial Sloan Kettering Cancer Center
Most cited
By later US patents
- Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites18US 9,133,480 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Nitrogen monoxide production suppressor10US 6,051,613 ANippon Zoki Pharmaceutical Co., Ltd. · 2000
- Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites7US 9,879,231 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2018
- Replication competent attenuated vaccinia viruses with deletion of thymidine kinase with and without the expression of human Flt3L or GM-CSF for cancer immunotherapy6US 10,512,662 B2Memorial Sloan Kettering Cancer Center · 2019
- Engineered immunostimulatory bacterial strains and uses thereof3US 11,242,528 B2Actym Therapeutics, Inc. · 2022